Published in J Clin Invest on April 01, 2010
Whole-exome sequencing-based discovery of STIM1 deficiency in a child with fatal classic Kaposi sarcoma. J Exp Med (2010) 2.70
Virus-encoded microRNAs. Virology (2011) 2.28
Generation of a doxycycline-inducible KSHV producer cell line of endothelial origin: maintenance of tight latency with efficient reactivation upon induction. J Virol Methods (2011) 2.25
Construction and manipulation of a new Kaposi's sarcoma-associated herpesvirus bacterial artificial chromosome clone. J Virol (2012) 1.89
Viral latency and its regulation: lessons from the gamma-herpesviruses. Cell Host Microbe (2010) 1.70
A unique herpesviral transcriptional program in KSHV-infected lymphatic endothelial cells leads to mTORC1 activation and rapamycin sensitivity. Cell Host Microbe (2013) 1.69
Human viral oncogenesis: a cancer hallmarks analysis. Cell Host Microbe (2014) 1.42
KSHV 2.0: a comprehensive annotation of the Kaposi's sarcoma-associated herpesvirus genome using next-generation sequencing reveals novel genomic and functional features. PLoS Pathog (2014) 1.37
Disrupting galectin-1 interactions with N-glycans suppresses hypoxia-driven angiogenesis and tumorigenesis in Kaposi's sarcoma. J Exp Med (2012) 1.31
The spring-loaded genome: nucleosome redistributions are widespread, transient, and DNA-directed. Genome Res (2013) 1.27
Reactive oxygen species hydrogen peroxide mediates Kaposi's sarcoma-associated herpesvirus reactivation from latency. PLoS Pathog (2011) 1.27
Clinical Manifestations of Kaposi Sarcoma Herpesvirus Lytic Activation: Multicentric Castleman Disease (KSHV-MCD) and the KSHV Inflammatory Cytokine Syndrome. Front Microbiol (2012) 1.25
Inherited human OX40 deficiency underlying classic Kaposi sarcoma of childhood. J Exp Med (2013) 1.14
Hsp70 Isoforms Are Essential for the Formation of Kaposi's Sarcoma-Associated Herpesvirus Replication and Transcription Compartments. PLoS Pathog (2015) 1.14
ORF45 of Kaposi's sarcoma-associated herpesvirus inhibits phosphorylation of interferon regulatory factor 7 by IKKε and TBK1 as an alternative substrate. J Virol (2012) 1.10
Human herpesvirus 8-associated neoplasms: the roles of viral replication and antiviral treatment. Curr Opin Infect Dis (2011) 1.09
Inhibition of cGAS DNA Sensing by a Herpesvirus Virion Protein. Cell Host Microbe (2015) 1.09
KSHV microRNAs mediate cellular transformation and tumorigenesis by redundantly targeting cell growth and survival pathways. PLoS Pathog (2013) 1.08
PI3Kγ mediates kaposi's sarcoma-associated herpesvirus vGPCR-induced sarcomagenesis. Cancer Cell (2011) 1.06
Viral microRNA target allows insight into the role of translation in governing microRNA target accessibility. Proc Natl Acad Sci U S A (2011) 1.05
Viruses and human cancer: from detection to causality. Cancer Lett (2010) 1.05
HIV-1 Tat promotes Kaposi's sarcoma-associated herpesvirus (KSHV) vIL-6-induced angiogenesis and tumorigenesis by regulating PI3K/PTEN/AKT/GSK-3β signaling pathway. PLoS One (2013) 1.05
mTOR inhibitors block Kaposi sarcoma growth by inhibiting essential autocrine growth factors and tumor angiogenesis. Cancer Res (2013) 1.04
Insights into the broad cellular effects of nelfinavir and the HIV protease inhibitors supporting their role in cancer treatment and prevention. Curr Opin Oncol (2013) 1.03
Direct and efficient cellular transformation of primary rat mesenchymal precursor cells by KSHV. J Clin Invest (2012) 1.01
Binding of the Kaposi's sarcoma-associated herpesvirus to the ephrin binding surface of the EphA2 receptor and its inhibition by a small molecule. J Virol (2014) 0.99
Evasion and subversion of interferon-mediated antiviral immunity by Kaposi's sarcoma-associated herpesvirus: an overview. J Virol (2011) 0.98
Kaposi's sarcoma-associated herpesvirus K-Rta exhibits SUMO-targeting ubiquitin ligase (STUbL) like activity and is essential for viral reactivation. PLoS Pathog (2013) 0.98
Molecular and cellular mechanisms of KSHV oncogenesis of Kaposi's sarcoma associated with HIV/AIDS. PLoS Pathog (2014) 0.97
Viral latency locus augments B-cell response in vivo to induce chronic marginal zone enlargement, plasma cell hyperplasia, and lymphoma. Blood (2013) 0.97
Protein arginine methyltransferase 1-directed methylation of Kaposi sarcoma-associated herpesvirus latency-associated nuclear antigen. J Biol Chem (2011) 0.97
Kaposi sarcoma-associated herpesvirus promotes tumorigenesis by modulating the Hippo pathway. Oncogene (2014) 0.96
Kaposi's sarcoma-associated herpesvirus (KSHV) latency-associated nuclear antigen regulates the KSHV epigenome by association with the histone demethylase KDM3A. J Virol (2013) 0.94
Activation of p90 ribosomal S6 kinases by ORF45 of Kaposi's sarcoma-associated herpesvirus is critical for optimal production of infectious viruses. J Virol (2014) 0.93
A novel mechanism inducing genome instability in Kaposi's sarcoma-associated herpesvirus infected cells. PLoS Pathog (2014) 0.93
Deep sequencing reveals direct targets of gammaherpesvirus-induced mRNA decay and suggests that multiple mechanisms govern cellular transcript escape. PLoS One (2011) 0.93
Tegument Proteins of Kaposi's Sarcoma-Associated Herpesvirus and Related Gamma-Herpesviruses. Front Microbiol (2012) 0.92
Ex vivo bioluminescence detection of alcelaphine herpesvirus 1 infection during malignant catarrhal fever. J Virol (2011) 0.92
The virome in host health and disease. Immunity (2015) 0.92
KSHV LANA--the master regulator of KSHV latency. Viruses (2014) 0.91
Kaposi's sarcoma herpesvirus K15 protein contributes to virus-induced angiogenesis by recruiting PLCγ1 and activating NFAT1-dependent RCAN1 expression. PLoS Pathog (2012) 0.91
Kaposi's sarcoma associated herpesvirus tegument protein ORF75 is essential for viral lytic replication and plays a critical role in the antagonization of ND10-instituted intrinsic immunity. PLoS Pathog (2014) 0.91
XLP: clinical features and molecular etiology due to mutations in SH2D1A encoding SAP. J Clin Immunol (2014) 0.90
Kaposi's sarcoma-associated herpesvirus K3 and K5 ubiquitin E3 ligases have stage-specific immune evasion roles during lytic replication. J Virol (2014) 0.90
Modeling human endothelial cell transformation in vascular neoplasias. Dis Model Mech (2013) 0.89
Post-Translational Modifications of Kaposi's Sarcoma-Associated Herpesvirus Regulatory Proteins - SUMO and KSHV. Front Microbiol (2012) 0.89
Reconstitution of immune responses against Kaposi sarcoma-associated herpesvirus. AIDS (2010) 0.89
A role for virally induced reactive oxygen species in Kaposi's sarcoma herpesvirus tumorigenesis. Antioxid Redox Signal (2012) 0.89
Phosphoproteomic analyses reveal signaling pathways that facilitate lytic gammaherpesvirus replication. PLoS Pathog (2013) 0.88
ORF45-Mediated Prolonged c-Fos Accumulation Accelerates Viral Transcription during the Late Stage of Lytic Replication of Kaposi's Sarcoma-Associated Herpesvirus. J Virol (2015) 0.88
Inhibition of Kaposi's sarcoma-associated herpesvirus lytic replication by HIV-1 Nef and cellular microRNA hsa-miR-1258. J Virol (2014) 0.87
Next-generation sequence analysis of the genome of RFHVMn, the macaque homolog of Kaposi's sarcoma (KS)-associated herpesvirus, from a KS-like tumor of a pig-tailed macaque. J Virol (2013) 0.87
A lytic viral long noncoding RNA modulates the function of a latent protein. J Virol (2013) 0.87
Exploitation of the complement system by oncogenic Kaposi's sarcoma-associated herpesvirus for cell survival and persistent infection. PLoS Pathog (2014) 0.86
Herpes simplex virus type 2 triggers reactivation of Kaposi's sarcoma-associated herpesvirus from latency and collaborates with HIV-1 Tat. PLoS One (2012) 0.86
Differences in Kaposi sarcoma-associated herpesvirus-specific and herpesvirus-non-specific immune responses in classic Kaposi sarcoma cases and matched controls in Sicily. Cancer Sci (2011) 0.86
Site-specific association with host and viral chromatin by Kaposi's sarcoma-associated herpesvirus LANA and its reversal during lytic reactivation. J Virol (2014) 0.86
Activation of the unfolded protein response by 2-deoxy-D-glucose inhibits Kaposi's sarcoma-associated herpesvirus replication and gene expression. Antimicrob Agents Chemother (2012) 0.86
Efficient infection of a human B cell line with cell-free Kaposi's sarcoma-associated herpesvirus. J Virol (2013) 0.84
The inflammatory kinase MAP4K4 promotes reactivation of Kaposi's sarcoma herpesvirus and enhances the invasiveness of infected endothelial cells. PLoS Pathog (2013) 0.84
Mutation of a C-terminal motif affects Kaposi's sarcoma-associated herpesvirus ORF57 RNA binding, nuclear trafficking, and multimerization. J Virol (2011) 0.84
Macaque homologs of EBV and KSHV show uniquely different associations with simian AIDS-related lymphomas. PLoS Pathog (2012) 0.84
Kaposi's sarcoma-associated herpesvirus ORF57 protein: exploiting all stages of viral mRNA processing. Viruses (2013) 0.84
Neutral lipid alterations in human herpesvirus 8-infected HUVEC cells and their possible involvement in neo-angiogenesis. BMC Microbiol (2015) 0.84
Productively infected murine Kaposi's sarcoma-like tumors define new animal models for studying and targeting KSHV oncogenesis and replication. PLoS One (2014) 0.83
An RNA element in human interleukin 6 confers escape from degradation by the gammaherpesvirus SOX protein. J Virol (2013) 0.83
Kaposi's sarcoma-associated herpesvirus ORF45 mediates transcriptional activation of the HIV-1 long terminal repeat via RSK2. J Virol (2014) 0.83
Novel Phosphorylations of IKKγ/NEMO. MBio (2012) 0.82
Cooperation between viral interferon regulatory factor 4 and RTA to activate a subset of Kaposi's sarcoma-associated herpesvirus lytic promoters. J Virol (2011) 0.82
Oncogenic herpesvirus KSHV Hijacks BMP-Smad1-Id signaling to promote tumorigenesis. PLoS Pathog (2014) 0.82
Differentially regulated splice variants and systems biology analysis of Kaposi's sarcoma-associated herpesvirus-infected lymphatic endothelial cells. Nucleic Acids Res (2011) 0.82
Shutoff of Host Gene Expression in Influenza A Virus and Herpesviruses: Similar Mechanisms and Common Themes. Viruses (2016) 0.81
Phosphoproteomic Analysis of KSHV-Infected Cells Reveals Roles of ORF45-Activated RSK during Lytic Replication. PLoS Pathog (2015) 0.81
K-bZIP Mediated SUMO-2/3 Specific Modification on the KSHV Genome Negatively Regulates Lytic Gene Expression and Viral Reactivation. PLoS Pathog (2015) 0.81
Systemic expression of Kaposi sarcoma herpesvirus (KSHV) Vflip in endothelial cells leads to a profound proinflammatory phenotype and myeloid lineage remodeling in vivo. PLoS Pathog (2015) 0.81
Human herpesvirus-8 infection leads to expansion of the preimmune/natural effector B cell compartment. PLoS One (2010) 0.81
Interference with the Autophagic Process as a Viral Strategy to Escape from the Immune Control: Lesson from Gamma Herpesviruses. J Immunol Res (2015) 0.81
Viral Bcl-2 Encoded by the Kaposi's Sarcoma-Associated Herpesvirus Is Vital for Virus Reactivation. J Virol (2015) 0.80
Kaposi's sarcoma-associated herpesvirus G-protein-coupled receptor prevents AU-rich-element-mediated mRNA decay. J Virol (2012) 0.80
Opposing regulation of PROX1 by interleukin-3 receptor and NOTCH directs differential host cell fate reprogramming by Kaposi sarcoma herpes virus. PLoS Pathog (2012) 0.80
Interplay between Kaposi's sarcoma-associated herpesvirus and the innate immune system. Cytokine Growth Factor Rev (2014) 0.80
Kaposi's sarcoma-associated herpesvirus transactivator Rta induces cell cycle arrest in G0/G1 phase by stabilizing and promoting nuclear localization of p27kip. J Virol (2013) 0.80
Inefficient Codon Usage Impairs mRNA Accumulation: the Case of the v-FLIP Gene of Kaposi's Sarcoma-Associated Herpesvirus. J Virol (2015) 0.80
Transcriptome-Wide Cleavage Site Mapping on Cellular mRNAs Reveals Features Underlying Sequence-Specific Cleavage by the Viral Ribonuclease SOX. PLoS Pathog (2015) 0.79
Fluorescent tagging and cellular distribution of the Kaposi's sarcoma-associated herpesvirus ORF45 tegument protein. J Virol (2014) 0.79
Identification of the Essential Role of Viral Bcl-2 for Kaposi's Sarcoma-Associated Herpesvirus Lytic Replication. J Virol (2015) 0.79
Metabolic reprogramming: a hallmark of viral oncogenesis. Oncogene (2015) 0.79
Role of host microRNAs in Kaposi's sarcoma-associated herpesvirus pathogenesis. Viruses (2014) 0.78
KSHV vCyclin counters the senescence/G1 arrest response triggered by NF-κB hyperactivation. Oncogene (2014) 0.78
Reduced human herpesvirus-8 oropharyngeal shedding associated with protease inhibitor-based antiretroviral therapy. J Clin Virol (2014) 0.78
Quantitative analysis of the bidirectional viral G-protein-coupled receptor and lytic latency-associated nuclear antigen promoter of Kaposi's sarcoma-associated herpesvirus. J Virol (2012) 0.78
Transmission of human herpesvirus type 8 infection within families in american indigenous populations from the Brazilian Amazon. J Infect Dis (2012) 0.78
Infection of human brain vascular pericytes (HBVPs) by Bartonella henselae. Med Microbiol Immunol (2012) 0.77
Kaposi's sarcoma herpesvirus oncogenesis is a notch better in 3D. Cell Host Microbe (2011) 0.77
A Review of Human Herpesvirus 8, the Kaposi's Sarcoma-Associated Herpesvirus, in the Pediatric Population. J Pediatric Infect Dis Soc (2013) 0.77
The importance of multiparasitism: examining the consequences of co-infections for human and animal health. Parasit Vectors (2015) 0.77
Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science (1994) 39.60
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell (1996) 23.99
Upstream and downstream of mTOR. Genes Dev (2004) 21.61
Identification of microRNAs of the herpesvirus family. Nat Methods (2005) 12.98
Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (HHV8). Proc Natl Acad Sci U S A (1996) 12.89
Lytic growth of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) in culture. Nat Med (1996) 12.11
Kaposi's sarcoma among persons with AIDS: a sexually transmitted infection? Lancet (1990) 9.11
Detection of herpesvirus-like DNA sequences in Kaposi's sarcoma in patients with and without HIV infection. N Engl J Med (1995) 8.52
Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med (2005) 7.83
Kaposi's sarcoma-associated herpesvirus infects endothelial and spindle cells. Nat Med (1995) 6.71
Kaposi's sarcoma-associated herpesvirus gene expression in endothelial (spindle) tumor cells. J Virol (1997) 6.61
Mucosal shedding of human herpesvirus 8 in men. N Engl J Med (2000) 6.59
Molecular mimicry of human cytokine and cytokine response pathway genes by KSHV. Science (1996) 6.57
Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. Nature (1997) 6.23
Restricted expression of Kaposi sarcoma-associated herpesvirus (human herpesvirus 8) genes in Kaposi sarcoma. Proc Natl Acad Sci U S A (1996) 6.00
KSHV antibodies among Americans, Italians and Ugandans with and without Kaposi's sarcoma. Nat Med (1996) 5.96
Kaposi's sarcoma-associated herpesvirus expresses an array of viral microRNAs in latently infected cells. Proc Natl Acad Sci U S A (2005) 5.88
The seroepidemiology of human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus): distribution of infection in KS risk groups and evidence for sexual transmission. Nat Med (1996) 5.56
Efficient persistence of extrachromosomal KSHV DNA mediated by latency-associated nuclear antigen. Science (1999) 5.55
G-protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator. Nature (1998) 5.24
A viral microRNA functions as an orthologue of cellular miR-155. Nature (2007) 5.09
Primary characterization of a herpesvirus agent associated with Kaposi's sarcomae. J Virol (1996) 5.05
p53 inhibition by the LANA protein of KSHV protects against cell death. Nature (2000) 4.74
Distribution of human herpesvirus-8 latently infected cells in Kaposi's sarcoma, multicentric Castleman's disease, and primary effusion lymphoma. Proc Natl Acad Sci U S A (1999) 4.52
Herpes-like sequences in HIV-infected and uninfected Kaposi's sarcoma patients. Science (1995) 4.51
A combined computational and microarray-based approach identifies novel microRNAs encoded by human gamma-herpesviruses. RNA (2006) 4.47
A cluster of latently expressed genes in Kaposi's sarcoma-associated herpesvirus. J Virol (1998) 4.23
The latent nuclear antigen of Kaposi sarcoma-associated herpesvirus targets the retinoblastoma-E2F pathway and with the oncogene Hras transforms primary rat cells. Nat Med (2000) 4.20
Kaposi's sarcoma-associated herpesvirus encodes an ortholog of miR-155. J Virol (2007) 4.19
The small G proteins of the Arf family and their regulators. Annu Rev Cell Dev Biol (2007) 4.14
Human herpesvirus KSHV encodes a constitutively active G-protein-coupled receptor linked to cell proliferation. Nature (1997) 4.12
Prevalence of Kaposi's sarcoma associated herpesvirus infection measured by antibodies to recombinant capsid protein and latent immunofluorescence antigen. Lancet (1996) 4.05
Cloning and identification of a microRNA cluster within the latency-associated region of Kaposi's sarcoma-associated herpesvirus. J Virol (2005) 4.01
Cell-homologous genes in the Kaposi's sarcoma-associated rhadinovirus human herpesvirus 8: determinants of its pathogenicity? J Virol (1997) 3.88
Herpesvirus-like DNA sequences in patients with Mediterranean Kaposi's sarcoma. Lancet (1995) 3.81
Angiogenic and HIV-inhibitory functions of KSHV-encoded chemokines. Science (1997) 3.70
Antibodies to butyrate-inducible antigens of Kaposi's sarcoma-associated herpesvirus in patients with HIV-1 infection. N Engl J Med (1996) 3.61
Use of the red fluorescent protein as a marker of Kaposi's sarcoma-associated herpesvirus lytic gene expression. Virology (2004) 3.60
The nucleosomal surface as a docking station for Kaposi's sarcoma herpesvirus LANA. Science (2006) 3.46
Kaposi's sarcoma-associated human herpesvirus-8 encodes homologues of macrophage inflammatory protein-1 and interleukin-6. Nat Med (1997) 3.44
Inefficient establishment of KSHV latency suggests an additional role for continued lytic replication in Kaposi sarcoma pathogenesis. J Clin Invest (2004) 3.39
Kaposi sarcoma herpesvirus-induced cellular reprogramming contributes to the lymphatic endothelial gene expression in Kaposi sarcoma. Nat Genet (2004) 3.38
Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group. N Engl J Med (1999) 3.38
Cyclin encoded by KS herpesvirus. Nature (1996) 3.32
The latency-associated nuclear antigen tethers the Kaposi's sarcoma-associated herpesvirus genome to host chromosomes in body cavity-based lymphoma cells. Virology (1999) 3.30
Identification of cellular genes targeted by KSHV-encoded microRNAs. PLoS Pathog (2007) 3.16
A novel viral mechanism for dysregulation of beta-catenin in Kaposi's sarcoma-associated herpesvirus latency. Nat Med (2003) 3.10
AIDS-Kaposi's sarcoma-derived cells express cytokines with autocrine and paracrine growth effects. Science (1989) 2.93
Kaposi's sarcoma-associated herpesvirus latent and lytic gene expression as revealed by DNA arrays. J Virol (2001) 2.87
Monoclonal origin of multicentric Kaposi's sarcoma lesions. N Engl J Med (1997) 2.81
Kaposi's-sarcoma-associated herpesvirus in HIV-negative Kaposi's sarcoma. Lancet (1995) 2.74
Charting latency transcripts in Kaposi's sarcoma-associated herpesvirus by whole-genome real-time quantitative PCR. J Virol (2002) 2.71
The size and conformation of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) DNA in infected cells and virions. J Virol (1996) 2.65
Angiogenesis and hematopoiesis induced by Kaposi's sarcoma-associated herpesvirus-encoded interleukin-6. Blood (1999) 2.65
Host range of Kaposi's sarcoma-associated herpesvirus in cultured cells. J Virol (2003) 2.60
Monocytes in Kaposi's sarcoma lesions are productively infected by human herpesvirus 8. J Virol (1997) 2.59
KSHV ORF K9 (vIRF) is an oncogene which inhibits the interferon signaling pathway. Oncogene (1997) 2.57
Differential viral protein expression in Kaposi's sarcoma-associated herpesvirus-infected diseases: Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease. Am J Pathol (2000) 2.55
Sexual transmission and the natural history of human herpesvirus 8 infection. N Engl J Med (1998) 2.52
Kaposi's sarcoma-associated herpesvirus infection prior to onset of Kaposi's sarcoma. AIDS (1996) 2.49
Lymphatic reprogramming of blood vascular endothelium by Kaposi sarcoma-associated herpesvirus. Nat Genet (2004) 2.47
The structure and coding organization of the genomic termini of Kaposi's sarcoma-associated herpesvirus. Virology (1997) 2.44
Tandem array-based expression screens identify host mRNA targets of virus-encoded microRNAs. Nat Genet (2008) 2.42
Characterization and cell cycle regulation of the major Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) latent genes and their promoter. J Virol (1999) 2.41
DNA binding and modulation of gene expression by the latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus. J Virol (2001) 2.41
KSHV vFLIP is essential for the survival of infected lymphoma cells. J Exp Med (2004) 2.39
Transcription profile of Kaposi's sarcoma-associated herpesvirus in primary Kaposi's sarcoma lesions as determined by real-time PCR arrays. Cancer Res (2003) 2.37
Lytic KSHV infection inhibits host gene expression by accelerating global mRNA turnover. Mol Cell (2004) 2.31
Close but distinct regions of human herpesvirus 8 latency-associated nuclear antigen 1 are responsible for nuclear targeting and binding to human mitotic chromosomes. J Virol (2001) 2.25
Transcriptional analysis of human herpesvirus-8 open reading frames 71, 72, 73, K14, and 74 in a primary effusion lymphoma cell line. Virology (1999) 2.23
Modulation of the NF-kappa B pathway by virally encoded death effector domains-containing proteins. Oncogene (1999) 2.21
Kaposi's sarcoma-associated herpesvirus LANA2 is a B-cell-specific latent viral protein that inhibits p53. J Virol (2001) 2.21
Latency-associated nuclear antigen (LANA) cooperatively binds to two sites within the terminal repeat, and both sites contribute to the ability of LANA to suppress transcription and to facilitate DNA replication. J Biol Chem (2002) 2.21
Activation of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) lytic replication by human cytomegalovirus. J Virol (2001) 2.20
Conservation of virally encoded microRNAs in Kaposi sarcoma--associated herpesvirus in primary effusion lymphoma cell lines and in patients with Kaposi sarcoma or multicentric Castleman disease. J Infect Dis (2007) 2.17
Angiogenic properties of Kaposi's sarcoma-derived cells after long-term culture in vitro. Science (1988) 2.17
A complex translational program generates multiple novel proteins from the latently expressed kaposin (K12) locus of Kaposi's sarcoma-associated herpesvirus. J Virol (1999) 2.16
NF-kappaB inhibits gammaherpesvirus lytic replication. J Virol (2003) 2.15
Regulation of KSHV lytic switch protein expression by a virus-encoded microRNA: an evolutionary adaptation that fine-tunes lytic reactivation. Cell Host Microbe (2009) 2.15
The human herpes virus 8-encoded viral FLICE inhibitory protein physically associates with and persistently activates the Ikappa B kinase complex. J Biol Chem (2002) 2.13
Herpes viral cyclin/Cdk6 complexes evade inhibition by CDK inhibitor proteins. Nature (1997) 2.10
Immune reconstitution inflammatory syndrome associated with Kaposi's sarcoma. J Clin Oncol (2005) 2.07
Expression of the open reading frame 74 (G-protein-coupled receptor) gene of Kaposi's sarcoma (KS)-associated herpesvirus: implications for KS pathogenesis. J Virol (1999) 2.07
Biology of Kaposi's sarcoma. Eur J Cancer (2001) 2.07
KSHV vFLIP binds to IKK-gamma to activate IKK. J Cell Sci (2003) 2.04
Identification of kaposin (open reading frame K12) as a human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus) transforming gene. J Virol (1998) 2.02
A Kaposi's sarcoma-associated herpesvirus-encoded cytokine homolog (vIL-6) activates signaling through the shared gp130 receptor subunit. J Biol Chem (1997) 2.00
The inhibitor of death receptor signaling, FLICE-inhibitory protein defines a new class of tumor progression factors. J Exp Med (1999) 1.98
The Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen binds to specific sequences at the left end of the viral genome through its carboxy-terminus. Virology (2001) 1.92
In-depth analysis of Kaposi's sarcoma-associated herpesvirus microRNA expression provides insights into the mammalian microRNA-processing machinery. J Virol (2009) 1.90
The kaposin B protein of KSHV activates the p38/MK2 pathway and stabilizes cytokine mRNAs. Science (2005) 1.88
Kaposi's sarcoma associated herpesvirus G protein-coupled receptor immortalizes human endothelial cells by activation of the VEGF receptor-2/ KDR. Cancer Cell (2003) 1.86
Expression and localization of human herpesvirus 8-encoded proteins in primary effusion lymphoma, Kaposi's sarcoma, and multicentric Castleman's disease. Virology (2000) 1.86
Recrudescent Kaposi's sarcoma after initiation of HAART: a manifestation of immune reconstitution syndrome. AIDS Patient Care STDS (2005) 1.84
Rapamycin is efficacious against primary effusion lymphoma (PEL) cell lines in vivo by inhibiting autocrine signaling. Blood (2006) 1.83
Human immunodeficiency virus-associated oral Kaposi's sarcoma. A heterogeneous cell population dominated by spindle-shaped endothelial cells. Am J Pathol (1993) 1.77
Transcriptional origin of Kaposi's sarcoma-associated herpesvirus microRNAs. J Virol (2006) 1.77